Glenohumeral Cortisone Injection

University of Washington

Status and phase: Completed; Phase 2

Conditions: Humeral Fractures

Treatments: Drug: kenalog; Drug: Lidocaine

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT04216017

P30AR072572 (U.S. NIH Grant/Contract)

STUDY00007576

Details and patient eligibility

About

The objective of this project is to determine if giving a cortisone injection to patients with proximal humerus fractures who have stiff shoulders recover their range of motion.

Full description

THis is a randomized control trial to determine if giving a cortisone injection to patients with proximal humerus fractures who have stiff shoulders recover their range of motion.

Enrollment: 9 patients

Sex: All

Ages: 18 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1.18-90

2. Proximal Humerus Fracture

3. Decreased range of motion at 6 wk follow-up

4. Likely to be available for follow up for 26 wks

Exclusion criteria

1. Known drug allergy to kenalog or lidocaine
2. Unable to complete functional outcome
3. Pregnant Women

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

9 participants in 2 patient groups, including a placebo group

Controls

Placebo Comparator group

Description:

Patients receiving lidocaine

Treatment:

Drug: Lidocaine

Cases

Active Comparator group

Description:

Patients receiving Kenalog

Treatment:

Drug: kenalog